Tomkins Susannah, Chapman Callum, Myland Melissa, Tham Rachel, de Nobrega Rachael, Jackson Brinley, Keshav Satish
NEMEA Centre of Excellence for Retrospective Studies, IQVIA, London, United Kingdom.
Chelsea and Westminster Hospital, London, United Kingdom.
PLoS One. 2017 Dec 15;12(12):e0189952. doi: 10.1371/journal.pone.0189952. eCollection 2017.
Patients with gastrointestinal disease may have comorbid iron deficiency anaemia (IDA) and an increased risk of hospitalisation and re-attendance in hospital. The purpose of this study was to determine if oral and intravenous (IV) treatment of IDA in patients with gastrointestinal disease attending hospital were associated with differential rates of subsequent re-attendance.
Data from the Clinical Practice Research Datalink (primary care) and Hospital Treatment Insights (secondary care) databases in England were used to conduct this retrospective cohort study. Patients with a coded gastrointestinal disease and IDA who attended hospital (inpatient or outpatient) and were dispensed oral or IV iron between 01/01/2010-31/10/2013 were included. Elective and emergency re-attendances in secondary care within 30 days of the initial attendance were determined. Demographics, medical diagnoses and treatments were extracted. Re-attendance rates following oral or IV iron were compared using chi-square tests and a step-wise logistic regression model to adjust for confounders. 2,844 patients contributed 6,294 initial attendances; 80% of patients received oral iron, 14% received intravenous iron, and 6% received both. Of initial attendances recording oral iron, 77% resulted in re-attendance in hospital, compared to 34% of those recording IV iron (unadjusted odds ratio [OR]: 0.16; adjusted OR: 0.52 [95% CI: 0.44-0.61]). Initial attendances using IV treatment were more likely to result in elective re-attendance (84%) than those recording oral treatment (43%) (p<0.001). Median length of stay in hospital tended to be shorter for patients using IV iron (1.4 days; interquartile range 0.5-3.6 days; oral iron: 5.1 days; interquartile range: 2.2-9.6 days).
Patients with gastrointestinal disease and IDA who received IV iron were less likely to re-attend hospital, more likely to re-attend electively, and tended to have a shorter length of stay in hospital. The mode of IDA treatment could have a real-world impact on healthcare utilisation.
患有胃肠道疾病的患者可能合并缺铁性贫血(IDA),且住院和再次入院的风险增加。本研究的目的是确定在就诊于医院的胃肠道疾病患者中,口服和静脉注射(IV)治疗IDA是否与后续再次入院率的差异有关。
利用英格兰临床实践研究数据链(初级保健)和医院治疗洞察(二级保健)数据库的数据进行这项回顾性队列研究。纳入2010年1月1日至2013年10月31日期间因编码的胃肠道疾病和IDA而就诊于医院(住院或门诊)并接受口服或静脉铁剂治疗的患者。确定初次就诊后30天内在二级保健机构的择期和急诊再次就诊情况。提取人口统计学、医学诊断和治疗信息。使用卡方检验和逐步逻辑回归模型比较口服或静脉铁剂治疗后的再次入院率,以调整混杂因素。2844名患者共有6294次初次就诊;80%的患者接受口服铁剂,14%接受静脉铁剂,6%两者都接受。记录口服铁剂的初次就诊中,77%导致再次入院,而记录静脉铁剂的初次就诊中这一比例为34%(未调整优势比[OR]:0.16;调整后OR:0.52[95%CI:0.44-0.61])。与记录口服治疗的初次就诊相比,采用静脉治疗的初次就诊更有可能导致择期再次就诊(84%对43%)(p<0.001)。使用静脉铁剂的患者住院中位时间往往较短(1.4天;四分位间距0.5-3.6天;口服铁剂:5.1天;四分位间距:2.2-9.6天)。
患有胃肠道疾病和IDA且接受静脉铁剂治疗的患者再次入院的可能性较小,更有可能择期再次就诊,且住院时间往往较短。IDA的治疗方式可能对医疗资源利用产生实际影响。